Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Boucher

Showing results (561-570 of 682) with videos related to

Pageof 69
Sort By:
American Journal of Physiology. Lung Cellular and Molecular Physiology|December 5, 2019
Inhibition of ATP hydrolysis restores airway surface liquid production in cystic fibrosis airway epitheliaCatharina van Heusden, Brian Button, Wayne H Anderson, et al.
Journal for Immunotherapy of Cancer|October 28, 2021
4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cellsEmiliano Roselli, Justin C Boucher, Gongbo Li, et al.
Human Mutation|January 1, 1997
Identification of a splice site mutation (2789 +5 G > A) associated with small amounts of normal CFTR mRNA and mild cystic fibrosisW E Highsmith, L H Burch, Z Zhou, et al.
American Journal of Respiratory and Critical Care Medicine|December 15, 2007
Development of chronic bronchitis and emphysema in beta-epithelial Na+ channel-overexpressing miceMarcus A Mall, Jack R Harkema, Joanna B Trojanek, et al.
Journal of Biomedical Science|July 11, 2024
Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damageHiroshi Kotani, Hiroko Oshima, Justin C Boucher, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 17, 2002
Pharmacology of INS37217 [P(1)-(uridine 5')-P(4)- (2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosisB R Yerxa, J R Sabater, C W Davis, et al.
Journal of Leukocyte Biology|November 10, 2023
NKG2D receptor signaling shapes T cell thymic educationCynthia Perez, Lourdes Plaza-Rojas, Justin C Boucher, et al.
Scientific Reports|July 28, 2016
Quantification of heterogeneity in lung disease with image-based pulmonary function testingCharlene S Stahr, Chaminda R Samarage, Martin Donnelley, et al.
Experimental Hematology & Oncology|September 28, 2024
Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancersHiroshi Kotani, Tomoyoshi Yamano, Justin C Boucher, et al.
The Journal of Clinical Investigation|February 6, 2002
Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patientsDieter Worlitzsch, Robert Tarran, Martina Ulrich, et al.
Pageof 69

Showing results (561-570 of 682) with videos related to

Sort By:
Pageof 69
American Journal of Physiology. Lung Cellular and Molecular Physiology|December 5, 2019
Inhibition of ATP hydrolysis restores airway surface liquid production in cystic fibrosis airway epitheliaCatharina van Heusden, Brian Button, Wayne H Anderson, et al.
Journal for Immunotherapy of Cancer|October 28, 2021
4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cellsEmiliano Roselli, Justin C Boucher, Gongbo Li, et al.
Human Mutation|January 1, 1997
Identification of a splice site mutation (2789 +5 G > A) associated with small amounts of normal CFTR mRNA and mild cystic fibrosisW E Highsmith, L H Burch, Z Zhou, et al.
American Journal of Respiratory and Critical Care Medicine|December 15, 2007
Development of chronic bronchitis and emphysema in beta-epithelial Na+ channel-overexpressing miceMarcus A Mall, Jack R Harkema, Joanna B Trojanek, et al.
Journal of Biomedical Science|July 11, 2024
Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damageHiroshi Kotani, Hiroko Oshima, Justin C Boucher, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 17, 2002
Pharmacology of INS37217 [P(1)-(uridine 5')-P(4)- (2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosisB R Yerxa, J R Sabater, C W Davis, et al.
Journal of Leukocyte Biology|November 10, 2023
NKG2D receptor signaling shapes T cell thymic educationCynthia Perez, Lourdes Plaza-Rojas, Justin C Boucher, et al.
Scientific Reports|July 28, 2016
Quantification of heterogeneity in lung disease with image-based pulmonary function testingCharlene S Stahr, Chaminda R Samarage, Martin Donnelley, et al.
Experimental Hematology & Oncology|September 28, 2024
Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancersHiroshi Kotani, Tomoyoshi Yamano, Justin C Boucher, et al.
The Journal of Clinical Investigation|February 6, 2002
Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patientsDieter Worlitzsch, Robert Tarran, Martina Ulrich, et al.
Pageof 69